|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Operating Activities: | ||
| Net loss | ||
| Stock-based compensation expense | ||
| Change in estimated fair value of warrant liability | ||
| Gain on settlement of warrant liability | ||
| Loss on issuance of related party convertible notes payable at fair value | ||
| Change in estimated fair value of related party convertible notes payable | ||
| Interest accrued on license payable | ||
| Prepaid assets and other current assets | ||
| Other assets | ||
| Accounts payable | ||
| Accrued compensation | ||
| Accrued interest | ||
| Other accrued expenses | ||
| Net cash used in operating activities | ||
| Financing Activities: | ||
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | ||
| Proceeds from issuance of shares of common stock under June 2025 Private Placement, net | ||
| Proceeds from issuance of shares of common stock under the Committed Equity Facility, net | ||
| Proceeds from the exercise of stock options | ||
| Proceeds from initial public offering, net of underwriting discounts and commissions | ||
| Payment of offering costs related to initial public offering | ||
| Proceeds from issuance of related party short-term loan | ||
| Payment of related party short-term loan | ||
| Proceeds from issuances of related party convertible notes payable | ||
| Proceeds from issuances of redeemable convertible preferred stock, net | ||
| Deferred offering costs | ||
| Net cash provided by financing activities | ||
| Net change in cash and cash equivalents | ||
| Cash and cash equivalents, beginning of period | ||
| Cash and cash equivalents, end of period | ||
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | ||
| Cash paid for income taxes | ||
| Supplemental Schedule of Noncash Financing Activities: | ||
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | ||
| Reclassification of warrant liability to equity upon exchange of not in-the-money Series B and Series C Redeemable Convertible Preferred Stock Warrants for warrants to purchase common stock | ||
| Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon initial public offering | ||
| Conversion of related party convertible notes payable into common stock upon initial public offering | ||
| Estimated fair market value of warrants issued to placement agent in connection with issuance of redeemable convertible preferred stock | ||
| Deferred offering costs, unpaid and accrued | ||
| Deferred offering costs charged against Committed Equity Facility |
Loading...
